CAR-T 细胞治疗在新型抗原靶点中前 30 天的感染并发症 Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days. PubMed 2021/12/14 发表Blood AdvQ1 · IF 7.7(JCR 2025) 人群:儿童人群:成人靶点:CD19靶点:CD22靶点:BCMA技术:CAR-T 46.9分 ★★★☆☆ 站内排序·非疗效